1Department of Regulatory Affairs, School of Pharmaceutical Sciences, MVN University, Palwal (NCR) – 121105, Haryana, India
2Department of Pharmacology, School of Pharmaceutical Sciences, MVN University, Palwal (NCR) – 121105, Haryana, India
*Corresponding author. E-mail address: shivali.rahi@mvn.edu.in (S Rahi)
Online Published on 02 February, 2026.
As a global standard for regulatory submissions, the electronic Common Technical Document (eCTD) has improved efficiency among health authorities and streamlined procedures for pharmaceutical and biological products. The introduction of eCTD version 4.0 represents a significant digital leap with enhanced lifecycle management, interoperability, and message-based architecture. This transition supports more effective data handling and fosters cross-border regulatory cooperation. eCTD 4.0 offers advantages such as reduced redundancy, real-time communication, and increased submission flexibility by moving away from document-centric models to a modular, data-centric framework. Regulatory agencies including the FDA, EMA, PMDA, and Health Canada are at various implementation stages, signaling global commitment to submission modernization. This review examines the evolution, benefits, challenges, and strategic opportunities associated with the implementation of eCTD 4.0 in global regulatory systems.
The transition to eCTD 4.0 marks a major advancement in regulatory submissions, offering a more flexible, interoperable, and data-driven framework. By addressing the limitations of earlier versions, it enables improved efficiency, communication, and global harmonization.
eCTD 4.0, Regulatory submissions, Lifecycle management, Digital transformation, Global harmonization, Regulatory agencies, FDA, ICH
